Merck & Co. secured FDA approval for Enflonsia (cesrovimab), a long-acting monoclonal antibody to prevent respiratory syncytial virus (RSV) lower respiratory tract disease in newborns and infants. This approval comes as the CDC’s Advisory Committee on Immunization Practices (ACIP) was abruptly disbanded, creating uncertainty around forthcoming vaccine recommendations. RSV remains a leading cause of infant hospitalization, underscoring the significance of timely immunization options despite regulatory disruptions.